Sustained efficacy and safety of adalimumab in psoriasis treatment: A retrospective study of 49 patients with and without a history of TNF-α antagonist treatment

Archives of Dermatology

Volumn 144, Issue 6, 2008, Pages 804-806

  Van, Livia ^b   Modi, Sapna V ^b   Yang, Deborah J ^b   Hsu, Sylvia ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; EFALIZUMAB; ETANERCEPT; INFLIXIMAB;

BACKACHE; CELLULITIS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEVER; HUMAN; INFLUENZA; LETTER; MEDICAL RECORD; PATIENT ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; PSORIASIS; PYELONEPHRITIS; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; TREATMENT DURATION; TREATMENT RESPONSE;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD11; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; INJECTIONS; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 45349101128     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.144.6.804     Document Type: Letter

References (5)

1. Graves JE, Nunley K, Heffernan MP. Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2). J Am Acad Dermatol. 2007;56(1):e55-e79.
2. Boehncke WH, Prinz J, Gottlieb AB. Biologic therapies for psoriasis: a systematic review. J Rheumatol. 2006;33(7):1447-1451.
3. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003;348(7):601-608.
4. HUMIRA (adalimumab) [package insert]. North Chicago, IL: Abbott Laboratories; 2004.
5. Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006;55(4):598-606.